Hematology Reports最新文献_第9页

Humoral and Cell-Mediated Responses to SARS-CoV-2 Vaccination in a Cohort of Immunodeficient Patients 一组免疫缺陷患者对接种 SARS-CoV-2 疫苗的体液和细胞介导反应

IF 0.9

Hematology Reports Pub Date : 2023-12-08 DOI: 10.3390/hematolrep15040071

Federica Plano, Mojtaba Shekarkar Azgomi, A. M. Corsale, Corinne Spoto, N. Caccamo, S. Meraviglia, Francesco Dieli, Paolo D’Angelo, A. Trizzino, Sergio Siragusa

{"title":"Humoral and Cell-Mediated Responses to SARS-CoV-2 Vaccination in a Cohort of Immunodeficient Patients","authors":"Federica Plano, Mojtaba Shekarkar Azgomi, A. M. Corsale, Corinne Spoto, N. Caccamo, S. Meraviglia, Francesco Dieli, Paolo D’Angelo, A. Trizzino, Sergio Siragusa","doi":"10.3390/hematolrep15040071","DOIUrl":"https://doi.org/10.3390/hematolrep15040071","url":null,"abstract":"This study delves into the intricate landscape of SARS-CoV-2 vaccine response in immunodeficient patients, focusing on the dynamics of both humoral and cell-mediated immunity. The cohort includes patients with common variable immunodeficiency (CVI), agammaglobulinemia (XLA), and combined immunodeficiency (CI). The findings reveal varying degrees of antibody production, with XLA patients exhibiting no measurable response but displaying a robust T-cell-mediated response. The study emphasizes the importance of considering both arms of the immune system in assessing vaccine immunogenicity, particularly in the context of immunodeficiency. The results challenge conventional measures of vaccine efficacy only based on antibody titers, highlighting the need for a more comprehensive understanding of the immune response in this vulnerable population. This research contributes valuable insights to guide clinical decisions regarding vaccination strategies, booster doses, and overall protection in immunodeficient individuals.","PeriodicalId":12829,"journal":{"name":"Hematology Reports","volume":"51 28","pages":""},"PeriodicalIF":0.9,"publicationDate":"2023-12-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138588033","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Blastic Plasmocytoid Dendritic Cell Neoplasm (BPDCN): Clinical Features and Histopathology with a Therapeutic Overview 大疱性浆细胞性树突状细胞肿瘤 (BPDCN)：临床特征和组织病理学及治疗概述

IF 0.9

Hematology Reports Pub Date : 2023-12-08 DOI: 10.3390/hematolrep15040070

Gerardo Cazzato, Marialessandra Capuzzolo, E. Bellitti, Giovanni De Biasi, A. Colagrande, Katia Mangialardi, F. Gaudio, G. Ingravallo

{"title":"Blastic Plasmocytoid Dendritic Cell Neoplasm (BPDCN): Clinical Features and Histopathology with a Therapeutic Overview","authors":"Gerardo Cazzato, Marialessandra Capuzzolo, E. Bellitti, Giovanni De Biasi, A. Colagrande, Katia Mangialardi, F. Gaudio, G. Ingravallo","doi":"10.3390/hematolrep15040070","DOIUrl":"https://doi.org/10.3390/hematolrep15040070","url":null,"abstract":"Blastic Plasmacytoid Dendritic Cell Neoplasms (BPDCNs) are a rare, highly aggressive hematological malignant neoplasm that primarily involve the skin, bone marrow, lymph nodes and even extra-nodal sites. The rarity and relative poor description of cases in the literature make it necessary to review and further studies that deeply investigate this entity not only in a histopathological but also molecular field. In August–September 2023, we searched MEDLINE, PubMed and Scopus for randomized controlled trials (RCTs), narrative and systematic reviews, meta-analyses, observational studies (either longitudinal or retrospective), and case series published in English in the last 25 years using the keywords BPDCN, PDCs, Blastic NK-cell lymphoma, agranular CD4+ NK leukemia/lymphoma, agranular CD4+ CD56+ hematodermic neoplasm/tumor. Despite the progress made in recent years in the diagnosis and biological understanding of the disease, until 2018 there was no clear consensus regarding its treatment and the main therapeutic schemes used were based on chemotherapy regimens already used in the treatment of lymphomas, acute lymphoblastic leukemia (ALL) and/or acute myeloid leukemia (AML). In this narrative review, we address the definition and epidemiological features of BPDCN, provide the different theories on the etiopathogenesis with particular attention to the presumed cell of origin, discuss the main clinical manifestations that provide a sign of its presence, summarize the main histopathological and immunophenotypic characteristics with special attention to the most important markers, and finally, we provide some of the most effective information on the therapeutic treatment modalities of BPDCN.","PeriodicalId":12829,"journal":{"name":"Hematology Reports","volume":"40 8","pages":""},"PeriodicalIF":0.9,"publicationDate":"2023-12-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138588490","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Platelet Microvesicles, Inflammation, and Coagulation Markers: A Pilot Study 血小板微泡、炎症和凝血标志物：一项试点研究

IF 0.9

Hematology Reports Pub Date : 2023-12-04 DOI: 10.3390/hematolrep15040069

A. Gidaro, Alessandro Palmerio Delitala, Roberto Manetti, Sonia Caccia, M. Soloski, Giorgio Lambertenghi Deliliers, D. Castro, Mattia Donadoni, Arianna Bartoli, Giuseppe Sanna, Luigi Bergamaschini, Roberto Castelli

{"title":"Platelet Microvesicles, Inflammation, and Coagulation Markers: A Pilot Study","authors":"A. Gidaro, Alessandro Palmerio Delitala, Roberto Manetti, Sonia Caccia, M. Soloski, Giorgio Lambertenghi Deliliers, D. Castro, Mattia Donadoni, Arianna Bartoli, Giuseppe Sanna, Luigi Bergamaschini, Roberto Castelli","doi":"10.3390/hematolrep15040069","DOIUrl":"https://doi.org/10.3390/hematolrep15040069","url":null,"abstract":"Background: Platelet “Microvesicles” (MVs) are studied for their role in blood coagulation and inflammation. The study aimed to establish if MVs are related to age, plasma levels of inflammation, coagulation, and fibrinolysis markers in healthy individuals. Methods: We prospectively enrolled volunteers aged over 18 years. MVs, plasma levels of C-reactive protein (CRP), Interleukin 6 (IL-6), Interleukin 10 (IL-10), Interleukin 17 (IL-17), and transforming growth factor β (TGF-β), fibrinogen, plasminogen activator inhibitor-1 (PAI-1), von Willebrand factor (VWF), homocysteine, factor VII (FVII), thrombin activatable fibrinolysis inhibitor (TAFI), and Protein S were tested. Results: A total of 246 individuals (median age 65 years (“IQR”54–72)) were evaluated. Both univariate analysis and logistic regression models showed that MVs positively correlate with age, CRP, IL-6, IL-10, IL-17, TGF-β, fibrinogen, PAI-1, VWF, FVII, and homocysteine, while inversely correlating with TAFI and Protein S. The ROC curve analysis performed to identify a cut off for MV values (700 kMP) showed a good accuracy with over-range cytokines fibrinolysis factor and coagulation markers. Conclusions: To the best of our knowledge, this study is the first to correlate MVs with an entire panel of cardiovascular risk factors in healthy individuals. A future possible role of MVs in screening exams is suggested.","PeriodicalId":12829,"journal":{"name":"Hematology Reports","volume":"44 23","pages":""},"PeriodicalIF":0.9,"publicationDate":"2023-12-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138602230","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Low-Intensity and Chemo-Free Treatments in Ph+ ALL: Progression-Free Survival Based on Indirect Comparisons. Ph+ ALL的低强度和无化疗治疗：基于间接比较的无进展生存期。

IF 0.9

Hematology Reports Pub Date : 2023-11-26 DOI: 10.3390/hematolrep15040068

Melania Rivano, Daniele Mengato, Marco Chiumente, Andrea Messori

{"title":"Low-Intensity and Chemo-Free Treatments in Ph+ ALL: Progression-Free Survival Based on Indirect Comparisons.","authors":"Melania Rivano, Daniele Mengato, Marco Chiumente, Andrea Messori","doi":"10.3390/hematolrep15040068","DOIUrl":"10.3390/hematolrep15040068","url":null,"abstract":"In Philadelphia chromosome-positive B-cell (Ph+) acute lymphoblastic leukemia (LLA), growing evidence has accumulated regarding the efficacy of low-intensity and chemo-free regimens. Our objective was to analyze all recent trials evaluating these treatments and to compare them in terms of efficacy. We applied the Shiny method, an artificial intelligence technique, to analyze Kaplan-Meier curves and reconstruct patient-level data. Reconstructed patient data were then evaluated through standard survival statistics and subjected to indirect head-to-head treatment comparisons. The endpoint was progression-free survival (PFS). Based on 432 reconstructed patients, eight trials were analyzed. The survival data from these trials were pooled into three types of treatments: (i) treatments based on tyrosine kinase inhibitors (TKIs) combined with reduced-intensity chemotherapy (denoted as TKICHE); (ii) TKIs associated with steroids with no chemotherapy (TKISTE); (iii) chemotherapy-free combinations of blinatumomab plus TKIs (TKIBLI). According to the Shiny method, the three PFS curves were reported in a single Kaplan-Meier graph and subjected to survival statistics. In terms of PFS, TKIBLI ranked first, TKICHE second, and TKISTE third; the differences between these three regimens were statistically significant. This multi-treatment Kaplan-Meier graph, generated through the Shiny method, summarized the current evidence on these treatments in both qualitative and quantitative terms.","PeriodicalId":12829,"journal":{"name":"Hematology Reports","volume":"15 4","pages":"670-683"},"PeriodicalIF":0.9,"publicationDate":"2023-11-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10743216/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138829317","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Angioimmunoblastic T-Cell Lymphoma after Treatment of Classic Hodgkin Lymphoma: A Case Report. 经典霍奇金淋巴瘤治疗后的血管免疫母细胞 T 细胞淋巴瘤：病例报告。

IF 0.9

Hematology Reports Pub Date : 2023-11-25 DOI: 10.3390/hematolrep15040067

Ken Tanaka, Hiroaki Miyoshi, Yusuke Yamashita, Ryuta Iwamoto, Yuma Yokoya, Yuichi Tochino, Fumiko Arakawa, Shinobu Tamura, Shin-Ichi Murata, Takashi Sonoki, Koichi Ohshima

{"title":"Angioimmunoblastic T-Cell Lymphoma after Treatment of Classic Hodgkin Lymphoma: A Case Report.","authors":"Ken Tanaka, Hiroaki Miyoshi, Yusuke Yamashita, Ryuta Iwamoto, Yuma Yokoya, Yuichi Tochino, Fumiko Arakawa, Shinobu Tamura, Shin-Ichi Murata, Takashi Sonoki, Koichi Ohshima","doi":"10.3390/hematolrep15040067","DOIUrl":"10.3390/hematolrep15040067","url":null,"abstract":"We report a case of a 24-year-old man who developed angioimmunoblastic T-cell lymphoma (AITL) after treatment for refractory lymphocyte-rich classic Hodgkin lymphoma (LR-CHL). This patient was treated with the BV+AVD (brentuximab vedotin, doxorubicin, vinblastine, and dacarbazine) protocol for LR-CHL but progressed before completing chemotherapy. The pathological imaging showed the typical findings of LR-CHL at the first onset and first progression. Rescue chemotherapy and high-dose chemotherapy combined with autologous hematopoietic stem cell transplantation (AHSCT) were performed for refractory LR-CHL, and complete remission was achieved. However, the recurrence was suspected 6 months after AHSCT. The pathological findings of the lymph node biopsy at this time were different from those of the previous two lymph node biopsies, demonstrating findings of AITL. The finding of the immunohistochemical staining and polymerase chain reaction results supported the diagnosis. Although it has been reported that the risk for the development of non-Hodgkin lymphoma after treatment for Hodgkin lymphoma is increased, most are B-cell lymphomas, and few cases of AITL have been reported. AITL is a type of peripheral T-cell lymphoma that generally occurs in middle-aged and elderly people and that rarely occurs in young people. Here, we were able to make an accurate diagnosis by performing re-examination even when recurrence of LR-CHL was suspected. As there are no detailed case reports of AITL developing into secondary non-Hodgkin lymphoma, here we report on an identified case.","PeriodicalId":12829,"journal":{"name":"Hematology Reports","volume":"15 4","pages":"662-669"},"PeriodicalIF":0.9,"publicationDate":"2023-11-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10742454/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138829316","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Red Cell Distribution Width and Prediabetes in Adults in Northern Sudan: A Case-Control Study. 苏丹北部成人红细胞分布宽度与前驱糖尿病:一项病例对照研究。

IF 0.9

Hematology Reports Pub Date : 2023-11-20 DOI: 10.3390/hematolrep15040066

Ahmed A Hassan, Bashir E Ahmed, Ishag Adam

{"title":"Red Cell Distribution Width and Prediabetes in Adults in Northern Sudan: A Case-Control Study.","authors":"Ahmed A Hassan, Bashir E Ahmed, Ishag Adam","doi":"10.3390/hematolrep15040066","DOIUrl":"10.3390/hematolrep15040066","url":null,"abstract":"Diabetes mellitus (DM) is a major public health issue worldwide. Red cell distribution width (RDW) has been reported to have predictive value in several diseases, including DM. Few data exist on the association between RDW and the prediabetic stage. Thus, the present study aimed to investigate the association between RDW and prediabetes in adults in Sudan. This case-control study was conducted in Northern Sudan in 2022. The cases (n = 107) were prediabetic patients categorized according to the level of glycated hemoglobin (HbA1c), which ranged from 5.7% to 6.4%, while the controls (n = 107) were healthy participants. A questionnaire was used to collect the data. Standard methods were used to measure the HbAIc level and RDW. Logistic regression analysis was performed. The median (interquartile range (IQR)) of the RDW was significantly higher in prediabetic patients than in the controls (14.5% [13.8-15.3%] vs. 14.1% [13.6-14.7%], p = 0.003). Sex, educational level, occupational status, marital status, cigarette smoking, alcohol consumption, family history of DM, and body mass index were not associated with prediabetes. In the multivariate-adjusted model, higher age and higher RDW were associated with prediabetes. A positive correlation was found between RDW and HbA1c levels (r = 0.19, p = 0.006). In conclusion, this study supports the use of RDW as a predictor of DM.","PeriodicalId":12829,"journal":{"name":"Hematology Reports","volume":"15 4","pages":"651-661"},"PeriodicalIF":0.9,"publicationDate":"2023-11-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10660754/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138175999","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Association of microRNA Polymorphisms with Toxicities Induced by Methotrexate in Children with Acute Lymphoblastic Leukemia. 急性淋巴细胞白血病患儿甲氨蝶呤诱导的microRNA多态性与毒性的关系

IF 0.9

Hematology Reports Pub Date : 2023-11-20 DOI: 10.3390/hematolrep15040065

Vasiliki Karpa, Kallirhoe Kalinderi, Liana Fidani, Athanasios Tragiannidis

{"title":"Association of microRNA Polymorphisms with Toxicities Induced by Methotrexate in Children with Acute Lymphoblastic Leukemia.","authors":"Vasiliki Karpa, Kallirhoe Kalinderi, Liana Fidani, Athanasios Tragiannidis","doi":"10.3390/hematolrep15040065","DOIUrl":"10.3390/hematolrep15040065","url":null,"abstract":"Methotrexate (MTX), a structurally related substance to folic acid, is an important chemotherapeutic agent used for decades in the treatment of pediatric acute lymphoblastic leukemia (ALL) and other types of cancer as non-Hodgkin lymphomas and osteosarcomas. Despite the successful outcomes observed, the primary drawback is the variability in the pharmacokinetics and pharmacodynamics between patients. The main adverse events related to its use are nephrotoxicity, mucositis, and myelosuppression, especially when used in high doses. The potential adverse reactions and toxicities associated with MTX are a cause for concern and may lead to dose reduction or treatment interruption. Genetic variants in MTX transport genes have been linked to toxicity. Pharmacogenetic studies conducted in the past focused on single nucleotide polymorphisms (SNPs) in the coding and 5'-regulatory regions of genes. Recent studies have demonstrated a significant role of microRNAs (miRNAs) in the transport and metabolism of drugs and in the regulation of target genes. In the last few years, the number of annotated miRNAs has continually risen, in addition to the studies of miRNA polymorphisms and MTX toxicity. Therefore, the objective of the present study is to investigate the role of miRNA variants related to MTX adverse effects.","PeriodicalId":12829,"journal":{"name":"Hematology Reports","volume":"15 4","pages":"634-650"},"PeriodicalIF":0.9,"publicationDate":"2023-11-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10660515/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138175997","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Composite Angioimmunoblastic T-Cell Lymphoma and Diffuse Large B-Cell Lymphoma Presenting with Distributive Shock. 复合血管免疫母细胞t细胞淋巴瘤和弥漫性大b细胞淋巴瘤表现为分布性休克。

IF 0.9

Hematology Reports Pub Date : 2023-11-16 DOI: 10.3390/hematolrep15040064

Nisha Hariharan, Alisha Kabadi, Michelle Don, Mazen Odish, Benjamin Heyman

引用次数: 0

A Review of Hematological Complications and Treatment in COVID-19. 新冠肺炎血液并发症及治疗综述。

IF 0.9

Hematology Reports Pub Date : 2023-10-13 DOI: 10.3390/hematolrep15040059

Armand N Yazdani, Arian Abdi, Prathosh Velpuri, Parth Patel, Nathaniel DeMarco, Devendra K Agrawal, Vikrant Rai

{"title":"A Review of Hematological Complications and Treatment in COVID-19.","authors":"Armand N Yazdani, Arian Abdi, Prathosh Velpuri, Parth Patel, Nathaniel DeMarco, Devendra K Agrawal, Vikrant Rai","doi":"10.3390/hematolrep15040059","DOIUrl":"10.3390/hematolrep15040059","url":null,"abstract":"COVID-19, caused by SARS-CoV-2, and its variants have spread rapidly across the globe in the past few years, resulting in millions of deaths worldwide. Hematological diseases and complications associated with COVID-19 severely impact the mortality and morbidity rates of patients; therefore, there is a need for oversight on what pharmaceutical therapies are prescribed to hematologically at-risk patients. Thrombocytopenia, hemoglobinemia, leukopenia, and leukocytosis are all seen at increased rates in patients infected with COVID-19 and become more prominent in patients with severe COVID-19. Further, COVID-19 therapeutics may be associated with hematological complications, and this became more important in immunocompromised patients with hematological conditions as they are at higher risk of hematological complications after treatment. Thus, it is important to understand and treat COVID-19 patients with underlying hematological conditions with caution. Hematological changes during COVID-19 infection and treatment are important because they may serve as biomarkers as well as to evaluate the treatment response, which will help in changing treatment strategies. In this literature review, we discuss the hematological complications associated with COVID-19, the mechanisms, treatment groups, and adverse effects of commonly used COVID-19 therapies, followed by the hematological adverse events that could arise due to therapeutic agents used in COVID-19.","PeriodicalId":12829,"journal":{"name":"Hematology Reports","volume":"15 4","pages":"562-577"},"PeriodicalIF":0.9,"publicationDate":"2023-10-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10594461/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49690063","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A Push to Consider Mantle Cell Lymphoma in Adults with Leukemia/Lymphoma with Blastoid Morphology. 推动考虑成人白血病/具有芽细胞形态的淋巴瘤的套细胞淋巴瘤。

IF 0.9

Hematology Reports Pub Date : 2023-10-13 DOI: 10.3390/hematolrep15040061

Nkechi Arinze, Nivin Omar, Amany Keruakous, Ravindra Kolhe, Natasha Savage

{"title":"A Push to Consider Mantle Cell Lymphoma in Adults with Leukemia/Lymphoma with Blastoid Morphology.","authors":"Nkechi Arinze, Nivin Omar, Amany Keruakous, Ravindra Kolhe, Natasha Savage","doi":"10.3390/hematolrep15040061","DOIUrl":"10.3390/hematolrep15040061","url":null,"abstract":"Mantle cell lymphoma (MCL) is an intermediate-grade B-cell lymphoma, representing 2.8% of all non-Hodgkin lymphomas in the US. It is associated with t(11;14)(q13; q23), which leads to the overexpression of cyclin D1, consequently promoting cell proliferation. MCL usually expresses CD19, CD20, CD43, surface immunoglobulins, FMC7, BCL2, cyclin D1, CD5, and SOX11. Herein is a case of a 67-year-old male, referred to our facility with shortness of breath, anemia (hemoglobin of 5.3 g/dL), thrombocytopenia (12 × 109/L), and leukocytosis (283 × 109/L). A peripheral blood smear showed marked lymphocytosis with blastoid morphology. Morphologic examination of the bone marrow biopsy revealed a diffuse sheet of blastoid cells expressing CD20 and CD10, but without CD5 or cyclin D1. Given these features, a differential diagnosis of diffuse large B-cell lymphoma (DLBCL) with germinal center derivation, high-grade follicular lymphoma, and Burkitt lymphoma was considered, with the latter not favored due to morphology. Additional studies revealed positive SOX11, and fluorescence in situ hybridization (FISH) studies detected t(11;14). These additional studies supported diagnosis of the blastoid variant of MCL. In conclusion, we present a unique and challenging case of MCL without cyclin D1 or CD5, but with an expression of CD10 and SOX11, along with t(11;14). Pathologists should explicitly consider the blastoid variant of MCL when dealing with mature B-cell neoplasms with blastoid morphology in adults, and utilize a broad panel of ancillary studies, including FISH and SOX11.","PeriodicalId":12829,"journal":{"name":"Hematology Reports","volume":"15 4","pages":"592-596"},"PeriodicalIF":0.9,"publicationDate":"2023-10-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10594516/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49690062","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0